Browse

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma

Cited 41 time in Web of Science Cited 46 time in Scopus
Authors
Kwak, Cheol; Park, Yong Hyun; Jeong, Chang Wook; Jeong, Hyeon; Lee, Sang Eun; Moon, Kyung Chul; Ku, Ja Hyeon
Issue Date
2006-10-27
Publisher
John Wiley & Sons
Citation
J Surg Oncol. 2007 Mar 15;95(4):317-23.
Keywords
AdultAgedAntineoplastic Agents/therapeutic useCarcinoma, Renal Cell/mortality/*secondary/therapyCell DifferentiationCohort StudiesCombined Modality TherapyDiagnosis, DifferentialFemaleHumans*ImmunotherapyInterferon-alpha/therapeutic useInterleukin-2/therapeutic useKidney Neoplasms/mortality/*pathology/therapyMaleMiddle AgedNeoplasm StagingNephrectomyPrognosisSarcoma/mortality/*pathology/therapySurvival RateTime Factors
Abstract
BACKGROUND: The objective of the current study was to determine the significance of sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma (RCC). METHODS: Patients with metastatic RCC were included in this study and were categorized according to sarcomatoid differentiation. RESULTS: Patients with sarcomatoid differentiation had more aggressive tumor characteristics than those without sarcomatoid differentiation. After immunotherapy, the median progression-free survival was 9.0 months (95% confidence interval [CI] 1.4-52.7) for patient without sarcomatoid differentiation and 3.2 months (95% CI 0.4-42.9) for patients with sarcomatoid differentiation, respectively (P=0.0001). The median overall survival was 22.2 months (95% CI 3.2-75.4) and 10.0 months (95% CI 0.7-60.1) in both groups. When comparing patients with sarcomatoid differentiation, there was no significant difference of overall survival in the immunotherapy group and the no immunotherapy group. Multivariate Cox proportional hazards model analysis showed that T stage (Hazard ratio [HR] 1.71; 95% CI 1.07-2.74; P=0.024), sarcomatoid differentiation (HR 2.18; 95% CI 1.30-3.66; P = 0.003), and the number of metastasis sites (HR 1.81; 95% CI 1.14-2.88; P=0.012) were independent predictors of progression-free survival. Sarcomatoid differentiation and the number of metastasis sites were independent prognostic predictors of overall survival. The estimated relative risks of sarcomatoid differentiation and the number of metastasis sites were 2.83 (95% CI 1.49-5.40; P=0.002) and 2.31 (95% CI 1.29-4.16; P=0.005), respectively. CONCLUSIONS: Our findings suggest that sarcomatoid differentiation is an important prognostic factor for immunotherapy in metastatic RCC.
ISSN
0022-4790 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17066434

https://hdl.handle.net/10371/15690
DOI
https://doi.org/10.1002/jso.20669
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse